Literature DB >> 23421901

A novel continuous powder aerosolizer (CPA) for inhalative administration of highly concentrated recombinant surfactant protein-C (rSP-C) surfactant to preterm neonates.

G Pohlmann1, P Iwatschenko, W Koch, H Windt, M Rast, M Gama de Abreu, F J H Taut, C De Muynck.   

Abstract

BACKGROUND: In pulmonary medicine, aerosolization of substances for continuous inhalation is confined to different classes of nebulizers with their inherent limitations. Among the unmet medical needs is the lack of an aerosolized surfactant preparation for inhalation by preterm neonates, to avoid the risks associated with endotracheal intubation and surfactant bolus instillation. In the present report, we describe a high-concentration continuous powder aerosolization system developed for delivery of inhalable surfactant to preterm neonates.
METHODS: The developed device uses a technique that allows efficient aerosolization of dry surfactant powder, generating a surfactant aerosol of high concentration. In a subsequent humidification step, the heated aerosol particles are covered with a surface layer of water. The wet surfactant aerosol is then delivered to the patient interface (e.g., nasal prongs) through a tube.
RESULTS: The performance characteristics of the system are given as mass concentration, dose rate, and size distribution of the generated aerosol. Continuous aerosol flows of about 0.84 L/min can be generated from dry recombinant surfactant protein-C surfactant, with concentrations of up to 12 g/m(3) and median particle sizes of the humidified particles in the range of 3 to 3.5 μm at the patient interface. The system has been successfully used in preclinical studies.
CONCLUSION: The device with its continuous high-concentration delivery is promising for noninvasive delivery of surfactant aerosol to neonates and has the potential for becoming a versatile disperser platform closing the gap between continuously operating nebulizers and discontinuously operating dry powder inhaler devices.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23421901     DOI: 10.1089/jamp.2012.0996

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  21 in total

1.  Application of an inline dry powder inhaler to deliver high dose pharmaceutical aerosols during low flow nasal cannula therapy.

Authors:  Dale Farkas; Michael Hindle; P Worth Longest
Journal:  Int J Pharm       Date:  2018-05-05       Impact factor: 5.875

Review 2.  Administration of dry powders during respiratory supports.

Authors:  Wei-Ren Ke; Rachel Yoon Kyung Chang; Philip Chi Lip Kwok; Patricia Tang; Lan Chen; Donghao Chen; Hak-Kim Chan
Journal:  Ann Transl Med       Date:  2021-04

3.  Development of an Inline Dry Powder Inhaler for Oral or Trans-Nasal Aerosol Administration to Children.

Authors:  Dale Farkas; Michael Hindle; Serena Bonasera; Karl Bass; Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-08-29       Impact factor: 2.849

4.  Generation of High Concentrations of Respirable Solid-Phase Aerosols from Viscous Fluids.

Authors:  Xin Heng; Donovan B Yeates
Journal:  Aerosol Sci Technol       Date:  2018-07-30       Impact factor: 2.908

5.  Development of high efficiency ventilation bag actuated dry powder inhalers.

Authors:  Srinivas R B Behara; P Worth Longest; Dale R Farkas; Michael Hindle
Journal:  Int J Pharm       Date:  2014-02-07       Impact factor: 5.875

6.  Development of an Inline Dry Powder Inhaler That Requires Low Air Volume.

Authors:  Dale Farkas; Michael Hindle; P Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-12-20       Impact factor: 2.849

7.  Use of analgesic and sedative drugs in VLBW infants in German NICUs from 2003-2010.

Authors:  Katrin Mehler; André Oberthuer; Christoph Haertel; Egbert Herting; Bernd Roth; Wolfgang Goepel
Journal:  Eur J Pediatr       Date:  2013-07-23       Impact factor: 3.183

8.  Development of a new technique for the efficient delivery of aerosolized medications to infants on mechanical ventilation.

Authors:  P Worth Longest; Geng Tian
Journal:  Pharm Res       Date:  2014-08-08       Impact factor: 4.200

Review 9.  Delivery and performance of surfactant replacement therapies to treat pulmonary disorders.

Authors:  Nashwa El-Gendy; Anubhav Kaviratna; Cory Berkland; Prajnaparamita Dhar
Journal:  Ther Deliv       Date:  2013-08

10.  Performance of Low Air Volume Dry Powder Inhalers (LV-DPI) when Aerosolizing Excipient Enhanced Growth (EEG) Surfactant Powder Formulations.

Authors:  Susan Boc; Mohammad A M Momin; Dale R Farkas; Worth Longest; Michael Hindle
Journal:  AAPS PharmSciTech       Date:  2021-04-15       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.